The aim of the antimicrobial use initiative is to formally measure and improve the appropriate use of antibiotics including selection of the right antibiotic for the right clinical condition for the right duration. HMS seeks to decrease antibiotic-related complications and decrease antimicrobial resistance on a population health basis by:
- ensuring that patients with uncomplicated community-acquired pneumonia (CAP) do not receive more than five days of antibiotics;
- reducing the use of inappropriate empiric broad-spectrum antibiotics for patients with uncomplicated CAP; and
- reducing the testing and treatment of asymptomatic bacteriuria (ASB).
Previously, HMS focused on reducing antibiotic-related complications and resistance by:
- reducing fluoroquinolone use in patients with a positive urine culture and uncomplicated CAP.
Antibiotic-resistant bacteria are a significant national threat, and their control has become a national priority. Therefore, in addition to our generous support from our sponsor, Blue Cross Blue Shield of Michigan (BCBSM) and Blue Care Network (BCN), HMS has partnered with the following national organizations to drive this initiative:
- Centers for Disease Control and Prevention (CDC)
- Agency for Healthcare Research and Quality (AHRQ)
- Gordon and Betty Moore Foundation
- The National Quality Forum (NQF)